APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IBS-C Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global IBS-C Drugs Industry Growth and Trends Forecast to 2032

Report ID 174001260120 December 2025127 pages

Choose your research edition.

Industry ResearchIBS-C Drugs Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal IBS-C Drugs Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal IBS-C Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IBS-C Drugs Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal IBS-C Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global IBS-C Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IBS-C Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IBS-C Drugs include Abbott Laboratories, Actavis Nordic A/S, Albireo Pharma Inc, Ardelyx, Inc, Astellas Pharmaceuticals, Bama-Geve, SLU, Catalent Pharmaceuticals Solutions, Ferring BV and Ironwood Pharmaceuticals, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global IBS-C Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The IBS-C Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global IBS-C Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to IBS-C Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global IBS-C Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

IBS-C Drugs Market by Company

Abbott Laboratories

Actavis Nordic A/S

Albireo Pharma Inc

Ardelyx, Inc

Astellas Pharmaceuticals

Bama-Geve, SLU

Catalent Pharmaceuticals Solutions

Ferring BV

Ironwood Pharmaceuticals, Inc

Norgine B.V

Novartis Pharma Ag

Ono Pharmaceutical Co., Ltd

Prometheus Laboratories Inc

Salix Pharmaceuticals Ltd

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Synthetic Biologics, Inc

Teva Pharmaceutical Industries

The Menarini Group

Yuhan Corp

Astrazeneca Plc

Nestle

IBS-C Drugs Segment by Type

Stimulant Laxatives

Linaclotide

Lubiprostone

Osmotic Laxatives

Others

IBS-C Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

IBS-C Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IBS-C Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IBS-C Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IBS-C Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IBS-C Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of IBS-C Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Stimulant Laxatives Table 2. Major Company of Linaclotide Table 3. Major Company of Lubiprostone Table 4. Major Company of Osmotic Laxatives Table 5. Major Company of Others Table 6. Global IBS-C Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 8. Global IBS-C Drugs Sales Market Share in Volume by Type (2021-2026) Table 9. Global IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 10. Global IBS-C Drugs Sales Market Share in Value by Type (2021-2026) Table 11. Global IBS-C Drugs Price by Type (2021-2026) & (US$/Unit) Table 12. Global IBS-C Drugs Sales by Type (2027-2032) & (K Units) Table 13. Global IBS-C Drugs Sales Market Share in Volume by Type (2027-2032) Table 14. Global IBS-C Drugs Sales by Type (2027-2032) & (US$ Million) Table 15. Global IBS-C Drugs Sales Market Share in Value by Type (2027-2032) Table 16. Global IBS-C Drugs Price by Type (2027-2032) & (US$/Unit) Table 17. North America IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 18. North America IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Europe IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 20. Europe IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 24. Latin America IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa IBS-C Drugs Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa IBS-C Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. IBS-C Drugs Industry Trends Table 28. IBS-C Drugs Industry Drivers Table 29. IBS-C Drugs Industry Opportunities and Challenges Table 30. IBS-C Drugs Industry Restraints Table 31. Global IBS-C Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global IBS-C Drugs Revenue Market Share by Company (2021-2026) Table 33. Global IBS-C Drugs Sales by Company (2021-2026) & (K Units) Table 34. Global IBS-C Drugs Sales Share by Company (2021-2026) Table 35. Global IBS-C Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global IBS-C Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global IBS-C Drugs Major Company Production Sites and Headquarters Table 38. Global IBS-C Drugs Company, Product Type & Application Table 39. Global IBS-C Drugs Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global IBS-C Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global IBS-C Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global IBS-C Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global IBS-C Drugs Sales Market Share in Volume by Region (2021-2026) Table 45. Global IBS-C Drugs Sales by Region (2021-2026) & (US$ Million) Table 46. Global IBS-C Drugs Sales Market Share in Value by Region (2021-2026) Table 47. Global IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global IBS-C Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global IBS-C Drugs Sales Market Share in Volume by Region (2027-2032) Table 50. Global IBS-C Drugs Sales by Region (2027-2032) & (US$ Million) Table 51. Global IBS-C Drugs Sales Market Share in Value by Region (2027-2032) Table 52. Global IBS-C Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global IBS-C Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 55. Global IBS-C Drugs Sales Market Share in Volume by Application (2021-2026) Table 56. Global IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 57. Global IBS-C Drugs Sales Market Share in Value by Application (2021-2026) Table 58. Global IBS-C Drugs Price by Application (2021-2026) & (US$/Unit) Table 59. Global IBS-C Drugs Sales by Application (2027-2032) & (K Units) Table 60. Global IBS-C Drugs Sales Market Share in Volume by Application (2027-2032) Table 61. Global IBS-C Drugs Sales by Application (2027-2032) & (US$ Million) Table 62. Global IBS-C Drugs Sales Market Share in Value by Application (2027-2032) Table 63. Global IBS-C Drugs Price by Application (2027-2032) & (US$/Unit) Table 64. North America IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 65. North America IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Europe IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 67. Europe IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 71. Latin America IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa IBS-C Drugs Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa IBS-C Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Abbott Laboratories Company Information Table 75. Abbott Laboratories Business Overview Table 76. Abbott Laboratories IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Abbott Laboratories IBS-C Drugs Product Portfolio Table 78. Abbott Laboratories Recent Development Table 79. Actavis Nordic A/S Company Information Table 80. Actavis Nordic A/S Business Overview Table 81. Actavis Nordic A/S IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Actavis Nordic A/S IBS-C Drugs Product Portfolio Table 83. Actavis Nordic A/S Recent Development Table 84. Albireo Pharma Inc Company Information Table 85. Albireo Pharma Inc Business Overview Table 86. Albireo Pharma Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Albireo Pharma Inc IBS-C Drugs Product Portfolio Table 88. Albireo Pharma Inc Recent Development Table 89. Ardelyx, Inc Company Information Table 90. Ardelyx, Inc Business Overview Table 91. Ardelyx, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Ardelyx, Inc IBS-C Drugs Product Portfolio Table 93. Ardelyx, Inc Recent Development Table 94. Astellas Pharmaceuticals Company Information Table 95. Astellas Pharmaceuticals Business Overview Table 96. Astellas Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Astellas Pharmaceuticals IBS-C Drugs Product Portfolio Table 98. Astellas Pharmaceuticals Recent Development Table 99. Bama-Geve, SLU Company Information Table 100. Bama-Geve, SLU Business Overview Table 101. Bama-Geve, SLU IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Bama-Geve, SLU IBS-C Drugs Product Portfolio Table 103. Bama-Geve, SLU Recent Development Table 104. Catalent Pharmaceuticals Solutions Company Information Table 105. Catalent Pharmaceuticals Solutions Business Overview Table 106. Catalent Pharmaceuticals Solutions IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio Table 108. Catalent Pharmaceuticals Solutions Recent Development Table 109. Ferring BV Company Information Table 110. Ferring BV Business Overview Table 111. Ferring BV IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Ferring BV IBS-C Drugs Product Portfolio Table 113. Ferring BV Recent Development Table 114. Ironwood Pharmaceuticals, Inc Company Information Table 115. Ironwood Pharmaceuticals, Inc Business Overview Table 116. Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio Table 118. Ironwood Pharmaceuticals, Inc Recent Development Table 119. Norgine B.V Company Information Table 120. Norgine B.V Business Overview Table 121. Norgine B.V IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Norgine B.V IBS-C Drugs Product Portfolio Table 123. Norgine B.V Recent Development Table 124. Novartis Pharma Ag Company Information Table 125. Novartis Pharma Ag Business Overview Table 126. Novartis Pharma Ag IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Novartis Pharma Ag IBS-C Drugs Product Portfolio Table 128. Novartis Pharma Ag Recent Development Table 129. Ono Pharmaceutical Co., Ltd Company Information Table 130. Ono Pharmaceutical Co., Ltd Business Overview Table 131. Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio Table 133. Ono Pharmaceutical Co., Ltd Recent Development Table 134. Prometheus Laboratories Inc Company Information Table 135. Prometheus Laboratories Inc Business Overview Table 136. Prometheus Laboratories Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Prometheus Laboratories Inc IBS-C Drugs Product Portfolio Table 138. Prometheus Laboratories Inc Recent Development Table 139. Salix Pharmaceuticals Ltd Company Information Table 140. Salix Pharmaceuticals Ltd Business Overview Table 141. Salix Pharmaceuticals Ltd IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio Table 143. Salix Pharmaceuticals Ltd Recent Development Table 144. Sucampo Pharmaceuticals Company Information Table 145. Sucampo Pharmaceuticals Business Overview Table 146. Sucampo Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio Table 148. Sucampo Pharmaceuticals Recent Development Table 149. Synergy Pharmaceuticals Company Information Table 150. Synergy Pharmaceuticals Business Overview Table 151. Synergy Pharmaceuticals IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Synergy Pharmaceuticals IBS-C Drugs Product Portfolio Table 153. Synergy Pharmaceuticals Recent Development Table 154. Synthetic Biologics, Inc Company Information Table 155. Synthetic Biologics, Inc Business Overview Table 156. Synthetic Biologics, Inc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Synthetic Biologics, Inc IBS-C Drugs Product Portfolio Table 158. Synthetic Biologics, Inc Recent Development Table 159. Teva Pharmaceutical Industries Company Information Table 160. Teva Pharmaceutical Industries Business Overview Table 161. Teva Pharmaceutical Industries IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio Table 163. Teva Pharmaceutical Industries Recent Development Table 164. The Menarini Group Company Information Table 165. The Menarini Group Business Overview Table 166. The Menarini Group IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. The Menarini Group IBS-C Drugs Product Portfolio Table 168. The Menarini Group Recent Development Table 169. Yuhan Corp Company Information Table 170. Yuhan Corp Business Overview Table 171. Yuhan Corp IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Yuhan Corp IBS-C Drugs Product Portfolio Table 173. Yuhan Corp Recent Development Table 174. Astrazeneca Plc Company Information Table 175. Astrazeneca Plc Business Overview Table 176. Astrazeneca Plc IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Astrazeneca Plc IBS-C Drugs Product Portfolio Table 178. Astrazeneca Plc Recent Development Table 179. Nestle Company Information Table 180. Nestle Business Overview Table 181. Nestle IBS-C Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Nestle IBS-C Drugs Product Portfolio Table 183. Nestle Recent Development Table 184. North America IBS-C Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 185. North America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 186. North America IBS-C Drugs Sales Market Share by Country (2021-2026) Table 187. North America IBS-C Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 188. North America IBS-C Drugs Sales Market Share Forecast by Country (2027-2032) Table 189. North America IBS-C Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 190. North America IBS-C Drugs Market Size by Country (2021-2026) & (US$ Million) Table 191. North America IBS-C Drugs Market Share by Country (2021-2026) Table 192. North America IBS-C Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 193. North America IBS-C Drugs Market Share Forecast by Country (2027-2032) Table 194. Europe IBS-C Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 195. Europe IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 196. Europe IBS-C Drugs Sales Market Share by Country (2021-2026) Table 197. Europe IBS-C Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 198. Europe IBS-C Drugs Sales Market Share Forecast by Country (2027-2032) Table 199. Europe IBS-C Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 200. Europe IBS-C Drugs Market Size by Country (2021-2026) & (US$ Million) Table 201. Europe IBS-C Drugs Market Share by Country (2021-2026) Table 202. Europe IBS-C Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 203. Europe IBS-C Drugs Market Share Forecast by Country (2027-2032) Table 204. Asia-Pacific IBS-C Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 205. Asia-Pacific IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 206. Asia-Pacific IBS-C Drugs Sales Market Share by Country (2021-2026) Table 207. Asia-Pacific IBS-C Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 208. Asia-Pacific IBS-C Drugs Sales Market Share Forecast by Country (2027-2032) Table 209. Asia-Pacific IBS-C Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 210. Asia-Pacific IBS-C Drugs Market Size by Country (2021-2026) & (US$ Million) Table 211. Asia-Pacific IBS-C Drugs Market Share by Country (2021-2026) Table 212. Asia-Pacific IBS-C Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 213. Asia-Pacific IBS-C Drugs Market Share Forecast by Country (2027-2032) Table 214. Latin America IBS-C Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 215. Latin America IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 216. Latin America IBS-C Drugs Sales Market Share by Country (2021-2026) Table 217. Latin America IBS-C Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 218. Latin America IBS-C Drugs Sales Market Share Forecast by Country (2027-2032) Table 219. Latin America IBS-C Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 220. Latin America IBS-C Drugs Market Size by Country (2021-2026) & (US$ Million) Table 221. Latin America IBS-C Drugs Market Share by Country (2021-2026) Table 222. Latin America IBS-C Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 223. Latin America IBS-C Drugs Market Share Forecast by Country (2027-2032) Table 224. Middle East and Africa IBS-C Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 225. Middle East and Africa IBS-C Drugs Sales by Country (2021-2026) & (K Units) Table 226. Middle East and Africa IBS-C Drugs Sales Market Share by Country (2021-2026) Table 227. Middle East and Africa IBS-C Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 228. Middle East and Africa IBS-C Drugs Sales Market Share Forecast by Country (2027-2032) Table 229. Middle East and Africa IBS-C Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 230. Middle East and Africa IBS-C Drugs Market Size by Country (2021-2026) & (US$ Million) Table 231. Middle East and Africa IBS-C Drugs Market Share by Country (2021-2026) Table 232. Middle East and Africa IBS-C Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 233. Middle East and Africa IBS-C Drugs Market Share Forecast by Country (2027-2032) Table 234. Key Raw Materials Table 235. Raw Materials Key Suppliers Table 236. IBS-C Drugs Distributors List Table 237. IBS-C Drugs Customers List Table 238. Research Programs/Design for This Report Table 239. Authors List of This Report Table 240. Secondary Sources Table 241. Primary Sources List of Figures Figure 1. IBS-C Drugs Image Figure 2. Global IBS-C Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IBS-C Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global IBS-C Drugs Sales (2021-2032) & (K Units) Figure 5. Stimulant Laxatives Image Figure 6. Global Stimulant Laxatives Sales YoY Growth (2021-2032) & (K Units) Figure 7. Linaclotide Image Figure 8. Global Linaclotide Sales YoY Growth (2021-2032) & (K Units) Figure 9. Lubiprostone Image Figure 10. Global Lubiprostone Sales YoY Growth (2021-2032) & (K Units) Figure 11. Osmotic Laxatives Image Figure 12. Global Osmotic Laxatives Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global IBS-C Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global IBS-C Drugs Market Share by Type 2025 VS 2032 Figure 17. North America IBS-C Drugs Sales Market Share in Volume by Type in 2025 Figure 18. North America IBS-C Drugs Sales Market Share in Value by Type in 2025 Figure 19. Europe IBS-C Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Europe IBS-C Drugs Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific IBS-C Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific IBS-C Drugs Sales Market Share in Value by Type in 2025 Figure 23. Latin America IBS-C Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Latin America IBS-C Drugs Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa IBS-C Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa IBS-C Drugs Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 IBS-C Drugs Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Pharmacies Image Figure 30. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 31. Online Pharmacies Image Figure 32. Global Online Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 33. Retail Pharmacies Image Figure 34. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global IBS-C Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global IBS-C Drugs Market Share by Application 2025 VS 2032 Figure 37. North America IBS-C Drugs Sales Market Share in Volume by Application in 2025 Figure 38. North America IBS-C Drugs Sales Market Share in Value by Application in 2025 Figure 39. Europe IBS-C Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Europe IBS-C Drugs Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific IBS-C Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific IBS-C Drugs Sales Market Share in Value by Application in 2025 Figure 43. Latin America IBS-C Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Latin America IBS-C Drugs Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa IBS-C Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa IBS-C Drugs Sales Market Share in Value by Application in 2025 Figure 47. North America IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America IBS-C Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America IBS-C Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe IBS-C Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe IBS-C Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific IBS-C Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific IBS-C Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America IBS-C Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America IBS-C Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa IBS-C Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa IBS-C Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa IBS-C Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa IBS-C Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. IBS-C Drugs Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. IBS-C Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant Laxatives
  • Linaclotide
  • Lubiprostone
  • Osmotic Laxatives
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Abbott Laboratories
  • Actavis Nordic A/S
  • Albireo Pharma Inc
  • Ardelyx, Inc
  • Astellas Pharmaceuticals
  • Bama-Geve, SLU
  • Catalent Pharmaceuticals Solutions
  • Ferring BV
  • Ironwood Pharmaceuticals, Inc
  • Norgine B.V
  • Novartis Pharma Ag
  • Ono Pharmaceutical Co., Ltd
  • Prometheus Laboratories Inc
  • Salix Pharmaceuticals Ltd
  • Sucampo Pharmaceuticals
  • Synergy Pharmaceuticals
  • Synthetic Biologics, Inc
  • Teva Pharmaceutical Industries
  • The Menarini Group
  • Yuhan Corp
  • Astrazeneca Plc
  • Nestle

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IBS-C Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global IBS-C Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 IBS-C Drugs Market by Type
  6. 1.3.1 Stimulant Laxatives
  7. 1.3.2 Linaclotide
  8. 1.3.3 Lubiprostone
  9. 1.3.4 Osmotic Laxatives
  10. 1.3.5 Others
  11. 1.4 Global IBS-C Drugs Market Size by Type
  12. 1.4.1 Global IBS-C Drugs Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global IBS-C Drugs Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global IBS-C Drugs Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America IBS-C Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe IBS-C Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific IBS-C Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America IBS-C Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa IBS-C Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 IBS-C Drugs Industry Trends
  2. 2.2 IBS-C Drugs Industry Drivers
  3. 2.3 IBS-C Drugs Industry Opportunities and Challenges
  4. 2.4 IBS-C Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by IBS-C Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by IBS-C Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by IBS-C Drugs Price (2021-2026)
  4. 3.4 Global IBS-C Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IBS-C Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global IBS-C Drugs Company, Product Type & Application
  7. 3.7 Global IBS-C Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IBS-C Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IBS-C Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IBS-C Drugs Tier 1, Tier 2, and Tier 3
4 IBS-C Drugs Regional Status and Outlook
  1. 4.1 Global IBS-C Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global IBS-C Drugs Historic Market Size by Region
  3. 4.2.1 Global IBS-C Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global IBS-C Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global IBS-C Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global IBS-C Drugs Forecasted Market Size by Region
  7. 4.3.1 Global IBS-C Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global IBS-C Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global IBS-C Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 IBS-C Drugs by Application
  1. 5.1 IBS-C Drugs Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global IBS-C Drugs Market Size by Application
  6. 5.2.1 Global IBS-C Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global IBS-C Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global IBS-C Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America IBS-C Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe IBS-C Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific IBS-C Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America IBS-C Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa IBS-C Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott Laboratories
  2. 6.1.1 Abbott Laboratories Company Information
  3. 6.1.2 Abbott Laboratories Business Overview
  4. 6.1.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Laboratories IBS-C Drugs Product Portfolio
  6. 6.1.5 Abbott Laboratories Recent Developments
  7. 6.2 Actavis Nordic A/S
  8. 6.2.1 Actavis Nordic A/S Company Information
  9. 6.2.2 Actavis Nordic A/S Business Overview
  10. 6.2.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
  12. 6.2.5 Actavis Nordic A/S Recent Developments
  13. 6.3 Albireo Pharma Inc
  14. 6.3.1 Albireo Pharma Inc Company Information
  15. 6.3.2 Albireo Pharma Inc Business Overview
  16. 6.3.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
  18. 6.3.5 Albireo Pharma Inc Recent Developments
  19. 6.4 Ardelyx, Inc
  20. 6.4.1 Ardelyx, Inc Company Information
  21. 6.4.2 Ardelyx, Inc Business Overview
  22. 6.4.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
  24. 6.4.5 Ardelyx, Inc Recent Developments
  25. 6.5 Astellas Pharmaceuticals
  26. 6.5.1 Astellas Pharmaceuticals Company Information
  27. 6.5.2 Astellas Pharmaceuticals Business Overview
  28. 6.5.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
  30. 6.5.5 Astellas Pharmaceuticals Recent Developments
  31. 6.6 Bama-Geve, SLU
  32. 6.6.1 Bama-Geve, SLU Company Information
  33. 6.6.2 Bama-Geve, SLU Business Overview
  34. 6.6.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
  36. 6.6.5 Bama-Geve, SLU Recent Developments
  37. 6.7 Catalent Pharmaceuticals Solutions
  38. 6.7.1 Catalent Pharmaceuticals Solutions Company Information
  39. 6.7.2 Catalent Pharmaceuticals Solutions Business Overview
  40. 6.7.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
  42. 6.7.5 Catalent Pharmaceuticals Solutions Recent Developments
  43. 6.8 Ferring BV
  44. 6.8.1 Ferring BV Company Information
  45. 6.8.2 Ferring BV Business Overview
  46. 6.8.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Ferring BV IBS-C Drugs Product Portfolio
  48. 6.8.5 Ferring BV Recent Developments
  49. 6.9 Ironwood Pharmaceuticals, Inc
  50. 6.9.1 Ironwood Pharmaceuticals, Inc Company Information
  51. 6.9.2 Ironwood Pharmaceuticals, Inc Business Overview
  52. 6.9.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
  54. 6.9.5 Ironwood Pharmaceuticals, Inc Recent Developments
  55. 6.10 Norgine B.V
  56. 6.10.1 Norgine B.V Company Information
  57. 6.10.2 Norgine B.V Business Overview
  58. 6.10.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Norgine B.V IBS-C Drugs Product Portfolio
  60. 6.10.5 Norgine B.V Recent Developments
  61. 6.11 Novartis Pharma Ag
  62. 6.11.1 Novartis Pharma Ag Company Information
  63. 6.11.2 Novartis Pharma Ag Business Overview
  64. 6.11.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
  66. 6.11.5 Novartis Pharma Ag Recent Developments
  67. 6.12 Ono Pharmaceutical Co., Ltd
  68. 6.12.1 Ono Pharmaceutical Co., Ltd Company Information
  69. 6.12.2 Ono Pharmaceutical Co., Ltd Business Overview
  70. 6.12.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
  72. 6.12.5 Ono Pharmaceutical Co., Ltd Recent Developments
  73. 6.13 Prometheus Laboratories Inc
  74. 6.13.1 Prometheus Laboratories Inc Company Information
  75. 6.13.2 Prometheus Laboratories Inc Business Overview
  76. 6.13.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
  78. 6.13.5 Prometheus Laboratories Inc Recent Developments
  79. 6.14 Salix Pharmaceuticals Ltd
  80. 6.14.1 Salix Pharmaceuticals Ltd Company Information
  81. 6.14.2 Salix Pharmaceuticals Ltd Business Overview
  82. 6.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
  84. 6.14.5 Salix Pharmaceuticals Ltd Recent Developments
  85. 6.15 Sucampo Pharmaceuticals
  86. 6.15.1 Sucampo Pharmaceuticals Company Information
  87. 6.15.2 Sucampo Pharmaceuticals Business Overview
  88. 6.15.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
  90. 6.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 6.16 Synergy Pharmaceuticals
  92. 6.16.1 Synergy Pharmaceuticals Company Information
  93. 6.16.2 Synergy Pharmaceuticals Business Overview
  94. 6.16.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
  96. 6.16.5 Synergy Pharmaceuticals Recent Developments
  97. 6.17 Synthetic Biologics, Inc
  98. 6.17.1 Synthetic Biologics, Inc Company Information
  99. 6.17.2 Synthetic Biologics, Inc Business Overview
  100. 6.17.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
  102. 6.17.5 Synthetic Biologics, Inc Recent Developments
  103. 6.18 Teva Pharmaceutical Industries
  104. 6.18.1 Teva Pharmaceutical Industries Company Information
  105. 6.18.2 Teva Pharmaceutical Industries Business Overview
  106. 6.18.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
  108. 6.18.5 Teva Pharmaceutical Industries Recent Developments
  109. 6.19 The Menarini Group
  110. 6.19.1 The Menarini Group Company Information
  111. 6.19.2 The Menarini Group Business Overview
  112. 6.19.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 The Menarini Group IBS-C Drugs Product Portfolio
  114. 6.19.5 The Menarini Group Recent Developments
  115. 6.20 Yuhan Corp
  116. 6.20.1 Yuhan Corp Company Information
  117. 6.20.2 Yuhan Corp Business Overview
  118. 6.20.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Yuhan Corp IBS-C Drugs Product Portfolio
  120. 6.20.5 Yuhan Corp Recent Developments
  121. 6.21 Astrazeneca Plc
  122. 6.21.1 Astrazeneca Plc Company Information
  123. 6.21.2 Astrazeneca Plc Business Overview
  124. 6.21.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
  126. 6.21.5 Astrazeneca Plc Recent Developments
  127. 6.22 Nestle
  128. 6.22.1 Nestle Company Information
  129. 6.22.2 Nestle Business Overview
  130. 6.22.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Nestle IBS-C Drugs Product Portfolio
  132. 6.22.5 Nestle Recent Developments
7 North America by Country
  1. 7.1 North America IBS-C Drugs Sales by Country
  2. 7.1.1 North America IBS-C Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America IBS-C Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America IBS-C Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America IBS-C Drugs Market Size by Country
  6. 7.2.1 North America IBS-C Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America IBS-C Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America IBS-C Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe IBS-C Drugs Sales by Country
  2. 8.1.1 Europe IBS-C Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe IBS-C Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe IBS-C Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe IBS-C Drugs Market Size by Country
  6. 8.2.1 Europe IBS-C Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe IBS-C Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe IBS-C Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific IBS-C Drugs Sales by Country
  2. 9.1.1 Asia-Pacific IBS-C Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific IBS-C Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific IBS-C Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific IBS-C Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific IBS-C Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific IBS-C Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific IBS-C Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America IBS-C Drugs Sales by Country
  2. 10.1.1 South America IBS-C Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America IBS-C Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America IBS-C Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America IBS-C Drugs Market Size by Country
  6. 10.2.1 South America IBS-C Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America IBS-C Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America IBS-C Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa IBS-C Drugs Sales by Country
  2. 11.1.1 Middle East and Africa IBS-C Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa IBS-C Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa IBS-C Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa IBS-C Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa IBS-C Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa IBS-C Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa IBS-C Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 IBS-C Drugs Value Chain Analysis
  2. 12.1.1 IBS-C Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 IBS-C Drugs Production Mode & Process
  7. 12.2 IBS-C Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 IBS-C Drugs Distributors
  10. 12.2.3 IBS-C Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst